Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19
Sang Youl Rhee, Jeong-Woo Lee, Hyewon Nam, et al.
Diabetes & Metabolism Journal (2021) Vol. 45, Iss. 2, pp. 251-259
Open Access | Times Cited: 54

Showing 1-25 of 54 citing articles:

Diabetes, obesity, metabolism, and SARS-CoV-2 infection: the end of the beginning
Daniel J. Drucker
Cell Metabolism (2021) Vol. 33, Iss. 3, pp. 479-498
Open Access | Times Cited: 241
COVID-19 and metabolic disease: mechanisms and clinical management
Charlotte Steenblock, Peter E. H. Schwarz, Barbara Ludwig, et al.
The Lancet Diabetes & Endocrinology (2021) Vol. 9, Iss. 11, pp. 786-798
Open Access | Times Cited: 212
The Structure of the Membrane Protein of SARS-CoV-2 Resembles the Sugar Transporter SemiSWEET
Sunil Thomas
Pathogens and Immunity (2020) Vol. 5, Iss. 1, pp. 342-342
Open Access | Times Cited: 158
Diabetes, obesity, and insulin resistance in COVID-19: molecular interrelationship and therapeutic implications
Andrey Santos, Daniéla Oliveira Magro, Rosana Evangelista Poderoso, et al.
Diabetology & Metabolic Syndrome (2021) Vol. 13, Iss. 1
Open Access | Times Cited: 121
Risk phenotypes of diabetes and association with COVID-19 severity and death: a living systematic review and meta-analysis
Sabrina Schlesinger, Manuela Neuenschwander, Alexander Lang, et al.
Diabetologia (2021) Vol. 64, Iss. 7, pp. 1480-1491
Open Access | Times Cited: 94
Covid-19 and Diabetes: A Complex Bidirectional Relationship
Hermine Muniangi-Muhitu, Elina Akalestou, Victoria Salem, et al.
Frontiers in Endocrinology (2020) Vol. 11
Open Access | Times Cited: 92
Association Between Anti-diabetic Agents and Clinical Outcomes of COVID-19 in Patients with Diabetes: A Systematic Review and Meta-Analysis
Tiantian Han, Shaodi Ma, Chenyu Sun, et al.
Archives of Medical Research (2021) Vol. 53, Iss. 2, pp. 186-195
Open Access | Times Cited: 50
The Roles of Dipeptidyl Peptidase 4 (DPP4) and DPP4 Inhibitors in Different Lung Diseases: New Evidence
Tianli Zhang, Tong Xiang, Shijie Zhang, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 50
Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis
Benedetta Maria Bonora, Angelo Avogaro, Gian Paolo Fadini
Journal of Endocrinological Investigation (2021) Vol. 44, Iss. 7, pp. 1379-1386
Open Access | Times Cited: 44
Dipeptidyl peptidase 4 (DPP4) inhibitor and outcome from coronavirus disease 2019 (COVID-19) in diabetic patients: a systematic review, meta-analysis, and meta-regression
Timotius Ivan Hariyanto, Andree Kurniawan
Journal of Diabetes & Metabolic Disorders (2021) Vol. 20, Iss. 1, pp. 543-550
Open Access | Times Cited: 43
The Association Between Antidiabetic Agents and Clinical Outcomes of COVID-19 Patients With Diabetes: A Bayesian Network Meta-Analysis
Yidan Chen, Xingfei Lv, Sang Lin, et al.
Frontiers in Endocrinology (2022) Vol. 13
Open Access | Times Cited: 34
Role of Dipeptidyl Peptidase-4 (DPP4) on COVID-19 Physiopathology
Alba Sebastián-Martín, Belén G. Sánchez, José María Mora-Rodríguez, et al.
Biomedicines (2022) Vol. 10, Iss. 8, pp. 2026-2026
Open Access | Times Cited: 32
Mortality and Severity in COVID-19 Patients on ACEIs and ARBs—A Systematic Review, Meta-Analysis, and Meta-Regression Analysis
Romil Singh, Sawai Singh Rathore, Hira Khan, et al.
Frontiers in Medicine (2022) Vol. 8
Open Access | Times Cited: 29
DPP-4 Inhibitors as a savior for COVID-19 patients with diabetes
Snehasish Nag, Samanwita Mandal, Oindrila Mukherjee, et al.
Future Virology (2023) Vol. 18, Iss. 5, pp. 321-333
Open Access | Times Cited: 20
DPP-4 inhibition and COVID-19: From initial concerns to recent expectations
André Scheen
Diabetes & Metabolism (2020) Vol. 47, Iss. 2, pp. 101213-101213
Open Access | Times Cited: 43
Risk phenotypes of diabetes and association with COVID-19 severity and death: an update of a living systematic review and meta-analysis
Sabrina Schlesinger, Alexander Lang, Nikoletta Christodoulou, et al.
Diabetologia (2023) Vol. 66, Iss. 8, pp. 1395-1412
Open Access | Times Cited: 16
Non-insulin anti-diabetic agents in patients with type 2 diabetes and COVID-19: A Critical Appraisal of Literature
Awadhesh Kumar Singh, Ritu Singh, Banshi Saboo, et al.
Diabetes & Metabolic Syndrome Clinical Research & Reviews (2020) Vol. 15, Iss. 1, pp. 159-167
Open Access | Times Cited: 34
Short- and long-term prognosis of glycemic control in COVID-19 patients with type 2 diabetes
Kang Zhan, X Zhang, Boshi Wang, et al.
QJM (2022) Vol. 115, Iss. 3, pp. 131-139
Open Access | Times Cited: 21
Possible Role of Adenosine in COVID-19 Pathogenesis and Therapeutic Opportunities
Jonathan D. Geiger, Nabab Khan, Madhuvika Murugan, et al.
Frontiers in Pharmacology (2020) Vol. 11
Open Access | Times Cited: 31
Cardiometabolic Therapy and Mortality in Very Old Patients With Diabetes Hospitalized due to COVID-19
Juan Carlos Ramos Ramos, Luis M. Pérez‐Belmonte, Francisco Javier Carrasco-Sánchez, et al.
The Journals of Gerontology Series A (2021) Vol. 76, Iss. 8, pp. e102-e109
Open Access | Times Cited: 26
Decreased Circulating Dipeptidyl Peptidase-4 Enzyme Activity Is Prognostic for Severe Outcomes in Covid-19 Inpatients
Ákos Nádasdi, György Sinkovits, Ilona Bobek, et al.
Biomarkers in Medicine (2022) Vol. 16, Iss. 5, pp. 317-330
Open Access | Times Cited: 17
COVID-19 and Diabetes: A Comprehensive Review of Angiotensin Converting Enzyme 2, Mutual Effects and Pharmacotherapy
Lingli Xie, Ziying Zhang, Qian Wang, et al.
Frontiers in Endocrinology (2021) Vol. 12
Open Access | Times Cited: 23
Dipeptidyl peptidase-4 (DPP-IV) inhibitor was associated with mortality reduction in COVID-19 — A systematic review and meta-analysis
Ahmad Fariz Malvi Zamzam Zein, Wilson Matthew Raffaello
Primary care diabetes (2021) Vol. 16, Iss. 1, pp. 162-167
Open Access | Times Cited: 21
A systematic review and meta‐analysis of the use of renin‐angiotensin system drugs and COVID‐19 clinical outcomes: What is the evidence so far?
Amanj Kurdi, Nouf Abutheraa, Lina Akil, et al.
Pharmacology Research & Perspectives (2020) Vol. 8, Iss. 6
Open Access | Times Cited: 23
The management of type 2 diabetes before, during and after Covid-19 infection: what is the evidence?
Leszek Czupryniak, Dror Dicker, Roger Lehmann, et al.
Cardiovascular Diabetology (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 20
Page 1 - Next Page

Scroll to top